name: Table 7
title: Table 7. Standard Treatment Options for NSCLC

<table>

  <colgroup>
    <col width="28.57%">
    <col width="22.32%">
    <col width="49.10%">
  </colgroup>
  <thead>
    <tr>
      <th colspan="2" align="Center" scope="col">Stage</th>
      <th align="Center" scope="col">Standard Treatment Options  </th>
    </tr>
  </thead>
  <tfoot class="pdq-footer">
    <tr>
      <td colspan="3">ALK = anaplastic lymphoma kinase; BRAF = v-raf murine sarcoma viral oncogene homolog B1; EGFR = epidermal growth factor receptor; MEK = MAPK kinase 1; NSCLC = non-small cell lung cancer; PD-L1 = programmed death-ligand 1; TKI = tyrosine kinase inhibitors; TNM = T, size of tumor and any spread of cancer into nearby tissue; N, spread of cancer to nearby lymph nodes; M, metastasis or spread of cancer to other parts of body.</td>
    </tr>
  </tfoot>
  <tbody>
    <tr>
      <td colspan="2">Occult NSCLC</td>
      <td>Surgery

  </td>
    </tr>
    <tr>
      <td rowspan="2" colspan="2">Stage 0 NSCLC</td>
      <td>
        Surgery

  </td>
    </tr>
    <tr>
      <td>
        Endobronchial therapies
      </td>
    </tr>
    <tr>
      <td rowspan="2" colspan="2">Stages IA and IB NSCLC </td>
      <td>
        Surgery </td>
    </tr>
    <tr>
      <td>
        Radiation therapy
      </td>
    </tr>
    <tr>
      <td rowspan="4" colspan="2">Stages IIA and IIB NSCLC</td>
      <td>
        Surgery   </td>
    </tr>
    <tr>
      <td>
        Adjuvant chemotherapy
      </td>
    </tr>
    <tr>
      <td>
        Neoadjuvant chemotherapy
      </td>
    </tr>
    <tr>
      <td>
        Radiation therapy
      </td>
    </tr>
    <tr>
      <td rowspan="12">Stage IIIA NSCLC</td>
      <td rowspan="3">Resected or resectable disease</td>
      <td>
        Surgery  </td>
    </tr>
    <tr>
      <td>
        Neoadjuvant therapy
      </td>
    </tr>
    <tr>
      <td>
        Adjuvant therapy
      </td>
    </tr>
    <tr>
      <td rowspan="2">Unresectable disease</td>
      <td>
        Radiation therapy </td>
    </tr>
    <tr>
      <td>
        Chemoradiation therapy
      </td>
    </tr>
    <tr>
      <td rowspan="3">Superior sulcus tumors</td>
      <td>
        Radiation therapy alone    </td>
    </tr>
    <tr>
      <td>
        Surgery
      </td>
    </tr>
    <tr>
      <td>
        Chemoradiation therapy followed by surgery
      </td>
    </tr>
    <tr>
      <td rowspan="4">Tumors that invade the chest wall</td>
      <td>
        Surgery
      </td>
    </tr>
    <tr>
      <td>
        Surgery and radiation therapy
      </td>
    </tr>
    <tr>
      <td>
        Radiation therapy alone
      </td>
    </tr>
    <tr>
      <td>
        Chemotherapy combined with radiation therapy and/or surgery  
      </td>
    </tr>
    <tr>
      <td rowspan="4" colspan="2">Stages IIIB and IIIC NSCLC</td>
      <td>
        Sequential or concurrent chemotherapy and radiation therapy    </td>
    </tr>
    <tr>
      <td>
        Radiation therapy dose escalation for concurrent chemoradiation
      </td>
    </tr>
    <tr>
      <td>
        Additional systemic therapy before or after concurrent chemotherapy and radiation therapy
      </td>
    </tr>
    <tr>
      <td>
        Radiation therapy alone
      </td>
    </tr>
    <tr>
      <td rowspan="9" colspan="2">Newly Diagnosed Stage IV, Relapsed, and Recurrent NSCLC</td>
      <td>
        Cytotoxic combination chemotherapy   </td>
    </tr>
    <tr>
      <td>
        Combination chemotherapy with monoclonal antibodies
      </td>
    </tr>
    <tr>
      <td>
        Maintenance therapy following first-line chemotherapy (for patients with stable or responding disease after four cycles of platinum-based combination chemotherapy)</td>
    </tr>
    <tr>
      <td>
        EGFR tyrosine kinase inhibitors (for patients with <em>EGFR</em> mutations)</td>
    </tr>
    <tr>
      <td>
        ALK inhibitors (for patients with <em>ALK</em> translocations)</td>
    </tr>
    <tr>
      <td>
        ROS1 inhibitors (for patients with <em>ROS1</em> rearrangements)</td>
    </tr>
    <tr>
      <td>
        BRAFV600E and MEK inhibitors (for patients with BRAFV600E mutations
      </td>
    </tr>
    <tr>
      <td>
        Immune checkpoint inhibitor for PD-L1 expressing NSCLC. </td>
    </tr>
    <tr>
      <td>
        Local therapies and special considerations
      </td>
    </tr>
    <tr>
      <td rowspan="6" colspan="2">Progressive Stage IV, Relapsed, and Recurrent NSCLC</td>
      <td>
        Chemotherapy     </td>
    </tr>
    <tr>
      <td>
        EGFR-directed therapy
      </td>
    </tr>
    <tr>
      <td>
        ALK-directed TKI
      </td>
    </tr>
    <tr>
      <td>
        ROS1-directed therapy
      </td>
    </tr>
    <tr>
      <td>
        BRAFV600E and MEK inhibitors (for patients with BRAFV600E mutations)
      </td>
    </tr>
    <tr>
      <td>
        Immunotherapy
      </td>
    </tr>
  </tbody>
  </table>
